Published in Health Business Week, September 2nd, 2005
Net sales for the second quarter of 2005 increased 57.3% to $283.4 million, compared to $180.2 million reported in the second quarter of 2004.
The increase was due primarily to the acquisition of Inveresk Research Group, and also to continuing strong demand for research models and outsourced preclinical services. The impact of the stronger U.S. dollar relative to foreign currencies reduced the second-quarter net sales growth rate by approximately 2% compared to the company's earlier guidance.
Net income on a generally accepted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week